Sanofi (SNY) said Friday a European Medicines Agency committee recommended the approval of Cenrifki in the European Union to treat secondary progressive multiple sclerosis, a chronic autoimmune disorder.
The specific indication is for patients without relapses in the past two years.
The company said a final decision is expected in the coming months.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments